Structure-activity relationship analysis and therapeutic potential of peptide deformylase inhibitors

Current Opinion in Investigational Drugs

Volumn 5, Issue 8, 2004, Pages 809-822

  Boularot, Adrien ^a,b   Giglione, Carmela ^a   Artaud, Isabelle ^b   Meinnel, Thierry ^a  

^a CNRS   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

3D structure; Actinonin; Bioavailability; Hydroxamic acid; Metal binding group; Protease; Resistance

Indexed keywords

AMIDASE; ANTIINFECTIVE AGENT; CHELATING AGENT; ENZYME INHIBITOR; PEPTIDE DEFORMYLASE;

ANIMAL; ANTIBIOTIC RESISTANCE; CHEMISTRY; CONFORMATION; DRUG ANTAGONISM; HUMAN; METABOLISM; REVIEW; STRUCTURE ACTIVITY RELATION;

AMIDOHYDROLASES; ANIMALS; ANTI-BACTERIAL AGENTS; CHELATING AGENTS; DRUG RESISTANCE, BACTERIAL; ENZYME INHIBITORS; HUMANS; MOLECULAR CONFORMATION; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 14744301187     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (126)

1. Giglione C, Meinnel T: The situation on antimicrobial agents and chemotherapy in 2002: Highlights of the 42nd ICAAC. Exp Opin Ther Targets (2002) 6(6):691-697.
2. Rice LB: Do we really need new anti-infective drugs? Curr Opin Pharmacol (2003) 3(5):459-463.
3. Woodford N: Novel agents for the treatment of resistant Gram-positive infections. Expert Opin Investig Drugs (2003) 12(2):117-137.
4. McDevitt D, Rosenberg M: Exploiting genomics to discover new antibiotics. Trends Microbiol (2001) 9(12):611-617.
5. Hughes D: Exploiting genomics, genetics and chemistry to combat antibiotic resistance. Nat Rev Genet (2003) 4(6):432-441.
6. Miesel L, Greene J, Black TA: Genetic strategies for antibacterial drug discovery. Nat Rev Genet (2003) 4(6):442-456.
7. Giglione C, Pierre M, Meinnel T: Peptide deformylase as a target for new generation, broad spectrum antimicrobial agents. Mol Microbiol (2000) 36(6):1197-1205.
8. Yuan Z, Trias J, White RJ: Deformylase as a novel antibacterial target. Drug Disc Today (2001) 6(18):954-961.
9. Pei D: Peptide deformylase: A target for novel antibiotics? Emerging Ther Targets (2001) 5(1):23-40.
10. Guilloteau JP, Mathieu M, Giglione C, Blanc V, Dupuy A, Chevrier M, Gil P, Famechon A, Meinnel T, Mikol V: The crystal structures of four peptide deformylases bound to the antibiotic actinonin reveal two distinct types: A platform for the structure-based design of antibacterial agents. J Mol Biol (2002) 320(5):951-962.
11. Giglione C, Boularot A, Meinnel T: Protein N-terminal methionine excision. Cell Mol Life Sci (2004) 61(12):1455-1474.
12. Mazel D, Pochet S, Marliere P: Genetic characterization of polypeptide deformylase, a distinctive enzyme of eubacterial translation. EMBO J (1994) 13(4):914-923.
13. Meinnel T, Blanquet S: Evidence that peptide deformylase and methionyl-tRNA(fMet) formyltransferase are encoded within the same operon in Escherichia coli. J Bacteriol (1993) 175(23):7737-7740.
14. Meinnel T, Blanquet S: Characterization of the Thermus thermophilus locus encoding peptide deformylase and methionyl-tRNA(fMet) formyltransferase. J Bacteriol (1994) 176(23):7387-7390.
15. Meinnel T, Blanquet S, Dardel F: A new subclass of the zinc metalloproteases superfamily revealed by the solution structure of peptide deformylase. J Mol Biol (1996) 262(3):375-386.
16. Chan MK, Gong W, Rajagopalan PT, Hao B, Tsai CM, Pei D: Crystal structure of the Escherichia coli peptide deformylase. Biochemistry (1997) 36(45):13904-13909.
17. Becker A, Schlichting I, Kabsch W, Schultz S, Wagner AF: Structure of peptide deformylase and identification of the substrate binding site. J Biol Chem (1998) 273(19):11413-11416.
18. Dardel F, Ragusa S, Lazennec C, Blanquet S, Meinnel T: Solution structure of nickel-peptide deformylase. J Mol Biol (1998) 280(3):501-513.
19. Smith HK, Beckett RP, Clements JM, Doel S, East SP, Launchbury SB, Pratt LM, Spavold ZM, Thomas W, Todd RS, Whittaker M: Structureactivity relationships of the peptide deformylase inhibitor BB-3497: Modification of the metal binding group. Bioorg Med Chem Lett (2002) 12(24):3595- 3599.
20. Baldwin ET, Harris MS, Yem AW, Wolfe CL, Vosters AF, Curry KA, Murray RW, Bock JH, Marshall VP, Cialdella JI, Merchant MH et al: Crystal structure of type II peptide deformylase from Staphylococcus aureus. J Biol Chem (2002) 277(34):31163-31171.
21. Kreusch A, Spraggon G, Lee CC, Klock H, McMullan D, Ng K, Shin T, Vincent J, Warner I, Ericson C, Lesley SA: Structure analysis of peptide deformylases from Streptococcus pneumoniae, Staphylococcus aureus, Thermotoga maritima and Pseudomonas aeruginosa: Snapshots of the oxygen sensitivity of peptide deformylase. J Mol Biol (2003) 330(2):309-321.
22. Groche D, Becker A, Schlichting I, Kabsch W, Schultz S, Wagner AF: Isolation and crystallization of functionally competent Escherichia coli peptide deformylase forms containing either iron or nickel in the active site. Biochem Biophys Res Commun (1998) 246(2):342-346.
23. Rajagopalan PTR, Yu XC, Pei D: Peptide deformylase: A new type of mononuclear iron protein. J Am Chem Soc (1997) 119(50):12418- 12419.
24. White RJ, Margolis PS, Trias J, Yuan Z: Targeting metalloenzymes: A strategy that works. Curr Opin Pharmacol (2003) 3(5):502-507.
25. Leung D, Abbenante G, Fairlie DP: Protease inhibitors: Current status and future prospects. J Med Chem (2000) 43(3):305-341.
26. Schechter I, Berger A: On the size of the active site in proteases. I. Papain. Bochem Biophys Res Commun (1967) 27(2):157-162.
27. Becker A, Schlichting I, Kabsch W, Groche D, Schultz S, Wagner AF: Iron center, substrate recognition and mechanism of peptide deformylase. Nat Struct Biol (1998) 5(12):1053-1058.
28. Rajagopalan PT, Grimme S, Pei D: Characterization of cobalt(II)-substituted peptide deformylase: Function of the metal ion and the catalytic residue Glu-133. Biochemistry (2000) 39(4):779-790.
29. Hu YJ, Wei Y, Zhou Y, Rajagopalan PTR, Pei D: Determination of substrate specificity for peptide deformylase through the screening of a combinatorial peptide library. Biochemistry (1999) 38(2):643-650.
30. Ragusa S, Mouchet P, Lazennec C, Dive V, Meinnel T: Substrate recognition and selectivity of peptide deformylase. Similarities and differences with metzincins and thermolysin. J Mol Biol (1999) 289(5):1445-1457.
31. Meinnel T, Patiny L, Ragusa S, Blanquet S: Design and synthesis of substrate analogue inhibitors of peptide deformylase. Biochemistry (1999) 38(14):4287-4295.
32. Wang P, Snavley DF, Freitas MA, Pei D: Screening combinatorial libraries for optimal enzyme substrates by mass spectrometry. Rapid Commun Mass Spectrom (2001) 15(14):1166-1171.
33. Wang P, Arabaci G, Pei D: Rapid sequencing of library-derived peptides by partial edman degradation and mass spectrometry. J Combinatorial Chem (2001) 3(3):251-254.
34. Wei Y, Pei D: Activation of antibacterial prodrugs by peptide deformylase. Bioorg Med Chem Lett (2000) 10(10):1073-1076.
35. Durand DJ, Gordon Green B, O'Connell JF, Grant SK: Peptide aldehyde inhibitors of bacterial peptide deformylases. Arch Biochem Biophys (1999) 367(2):297-302.
36. Hu YJ, Rajagopalan PT, Pei D: H-phosphonate derivatives as novel peptide deformylase inhibitors. Bioorg Med Chem Lett (1998) 8(18):2479-2482.
37. Hao B, Gong W, Rajagopalan PT, Zhou Y, Pei D, Chan MK: Structural basis for the design of antibiotics targeting peptide deformylase. Biochemistry (1999) 38(15):4712-4719.
38. Roques BP, Fournie-Zaluski MC, Soroca E, Lecomte JM, Malfroy B, Llorens C, Schwartz JC: The enkephalinase inhibitor thiorphan shows antinociceptive activity in mice. Nature (1980) 288(5788):286-288.
39. Huntington KM, Yi T, Wei Y, Pei D: Synthesis and antibacterial activity of peptide deformylase inhibitors. Biochemistry (2000) 39(15):4543-4551.
40. Wei Y, Yi T, Huntington KM, Chaudhury C, Pei D: Identification of a potent peptide deformylase inhibitor from a rationally designed combinatorial library. J Combinatorial Chem (2000) 2(6):650-657.
41. Chu M, Mierzwa R, He L, Xu L, Gentile F, Taerracciano J, Patel M, Miesel L, Bohanon S, Kravec C, Cramer C et al: Isolation and structure elucidation of two novel deformylase inhibitors produced by Streptomyces sp. Tetrahedron Lett (2001) 42(21):3549-3551.
42. Coats RA, Lee SL, Davis KA, Patel KM, Rhoads EK, Howard MH: Stereochemical definition and chirospecific synthesis of the peptide deformylase inhibitor Sch 382583. J Org Chem (2004) 69(5):1734-1737.
43. Jayasekera MM, Kendall A, Shammas R, Dermyer M, Tomala M, Shapiro MA, Holler TP: Novel nonpeptidic inhibitors of peptide deformylase. Arch Biochem Biophys (2000) 381(2):313-316.
44. Muri EM, Nieto MJ, Sindelar RD, Williamson JS: Hydroxamic acids as pharmacological agents. Curr Med Chem (2002) 9(17):1631-1653.
45. Gordon JJ, Kelly BK, Miller GA: Actinonin: An antibiotic substance produced by an actinomycete. Nature (1962) 195:701-702.
46. Chen DZ, Patel DV, Hackbarth CJ, Wang W, Dreyer G, Young DC, Margolis PS, Wu C, Ni ZJ, Trias J, White RJ et al : Actinonin, a naturally occurring antibacterial agent, is a potent deformylase inhibitor. Biochemistry (2000) 39(6):1256-1262.
47. Chan PF, O'Dwyer KM, Palmer LM, Ambrad JD, Ingraham KA, So C, Lonetto MA, Biswas S, Rosenberg M, Holmes DJ, Zalacain M: Characterization of a novel fucose-regulated promoter (PfcsK) suitable for gene essentiality and antibacterial mode-of-action studies in Streptococcus pneumoniae. J Bacteriol (2003) 185(6):2051-2058.
48. Jain R, Sundram A, Lopez S, Neckermann G, Wu C, Hackbarth C, Chen D, Wang W, Ryder NS, Weidmann B, Patel D et al: α-Substituted hydroxamic acids as novel bacterial deformylase inhibitor-based antibacterial agents. Bioorg Med Chem Lett (2003) 13(23):4223-4228.
49. Clements JM, Beckett RP, Brown A, Catlin G, Lobell M, Palan S, Thomas W, Whittaker M, Wood S, Salama S, Baker PJ et al : Antibiotic activity and characterization of BB-3497, a novel peptide deformylase inhibitor. Antimicrob Agents Chemother (2001) 45(2):563-570.
50. Hu X, Nguyen KT, Verlinde CL, Hol WG, Pei D: Structure-based design of a macrocyclic inhibitor for peptide deformylase. J Med Chem (2003) 46(18):3771-3774.
51. Grant SK, Gordon Green B, Kozarich JW: Inhibition and structure-activity studies of methionine hydroxamic derivatives with bacterial peptide deformylase. Bioorg Chem (2001) 29(4):211-222.
52. Madison V, Duca J, Bennett F, Bohanon S, Cooper A, Chu M, Desai J, Girijavallabhan V, Hare R, Hruza A, Hendrata S et al : Binding affinities and geometries of various metal ligands in peptide deformylase inhibitors. Biophys Chem (2002) 101-102:239-247.
53. Ma D, Cook DN, Hearst JE, Nikaido H: Efflux pumps and drug resistance in Gram-negative bacteria. Trends Microbiol (1994) 2(12):489-493.
54. Sulavik MC, Houseweart C, Cramer C, Jiwani N, Murgolo N, Greene J, DiDomenico B, Shaw KJ, Miller GH, Hare R, Shimer G: Antibiotic susceptibility profiles of Escherichia coli strains lacking multidrug efflux pump genes. Antimicrob Agents Chemother (2001) 45(4):1126- 1136.
55. Sundaram A, Jain R, Lopez S, Wu C, Chen D, Ni ZJ, Hackbarth C, Wang W, Withers G, Patel D, With R et al : Optimization of chelator-based 3-R-butyl-succinate-prolines as deformylase inhibitors. ICAAC (2002) 42:Abs F-1669.
56. Thorarensen A, Deibel MR Jr, Rohrer DC, Vosters AF, Yem AW, Marshall VD, Lynn JC, Bohanon MJ, Tomich PK, Zurenko GE, Sweeney MT et al: Identification of novel potent hydroxamic acid inhibitors of peptidyl deformylase and the importance of the hydroxamic acid functionality on inhibition. Bioorg Med Chem Lett (2001) 11(11):1355-1358.
57. Davies SJ, Ayscough AP, Beckett RP, Bragg RA, Clements JM, Doel S, Grew C, Launchbury SB, Perkins GM, Pratt LM, Smith HK et al : Structure-activity relationships of the peptide deformylase inhibitor BB-3497: Modification of the methylene spacer and the P1′ side chain. Bioorg Med Chem Lett (2003) 13(16):2709-2713.
58. Apfel C, Banner DW, Bur D, Dietz M, Hirata T, Hubschwerlen C, Locher H, Page MG, Pirson W, Rosse G, Specklin JL: Hydroxamic acid derivatives as potent peptide deformylase inhibitors and antibacterial agents. J Med Chem (2000) 43(12):2324-2331.
59. Apfel CM, Evers S, Hubschwerlen C, Pirson W, Page MG, Keck W: Peptide deformylase as an antibacterial drug target: Assays for detection of its inhibition in Escherichia coli cell homogenates and intact cells. Antimicrob Agents Chemother (2001) 45(4):1053-1057.
60. Morissey I, Dencer C, Salman H, Leakey A: Activity of novel peptide deformylase (PDF) inhibitors against atypical bacterial respiratory pathogens. ICAAC (2002) 41 :Abs F-1678.
61. Hackbarth CJ, Chen DZ, Lewis JG, Clark K, Mangold JB, Cramer JA, Margolis PS, Wang W, Koehn J, Wu C, Lopez S et al : N-alkyl urea hydroxamic acids as a new class of peptide deformylase inhibitors with antibacterial activity. Antimicrob Agents Chemother (2002) 46(9):2752-2764.
62. East SP, Beckett RP, Brookings DC, Clements JM, Doel S, Keavey K, Pain G, Smith HK, Thomas W, Thompson AJ, Todd RS, Whittaker M: Peptide deformylase inhibitors with activity against respiratory tract pathogens. Bioorg Med Chem Lett (2004) 14(1):59-62.
63. Davies SJ, Ayscough AP, Beckett RP, Clements JM, Doel S, Pratt LM, Spavold ZM, Thomas SW, Whittaker M: Structure-activity relationships of the peptide deformylase inhibitor BB-3497: Modification of the P2′ and P3′ side chains. Bioorg Med Chem Lett (2003) 13(16):2715-2718.
64. Lofland D, Difuntorum S, Waller A, Clements JM, Weaver MK, Karlowsky JA, Johnson K: In vitro antibacterial activity of the peptide deformylase inhibitor BB-83698. J Antimicrob Chemother (2004) 53(4):664-668.
65. Green BG, Toney JH, Kozarich JW, Grant SK: Inhibition of bacterial peptide deformylase by biaryl acid analogs. Arch Biochem Biophys (2000) 375(2):355-358.
66. Smith KJ, Petit CM, Aubart K, Smyth M, McManus E, Jones J, Fosberry A, Lewis C, Lonetto M, Christensen SB: Structural variation and inhibitor binding in polypeptide deformylase from four different bacterial species. Protein Sci (2003) 12(2):349-360.
67. Xue CB, He X, Roderick J, DeGrado WF, Cherney RJ, Hardman KD, Nelson DJ, Copeland RA, Jaffee BD, Decicco CP: Design and synthesis of cyclic inhibitors of matrix metalloproteinases and TNF-α production. J Med Chem (1998) 41(11):1745-1748.
68. Cherney RJ, Wang L, Meyer DT, Xue CB, Arner EC, Copeland RA, Covington MB, Hardman KD, Wasserman ZR, Jaffee BD, Decicco CP: Macrocyclic hydroxamate inhibitors of matrix metalloproteinases and TNF-α production. Bioorg Med Chem Lett (1999) 9(9):1279-1284.
69. Apfel C, Banner DW, Bur D, Dietz M, Hubschwerlen C, Locher H, Marlin F, Masciadri R, Pirson W, Stalder H: 2-(2-Oxo-1,4-dihydro-2H- quinazolin-3-yl)- and 2-(2,2-dioxo-1,4-dihydro-2H-2λ6- benzo[1,2,6]-thiadiazin-3-yl)-N-hydroxy-acetamides as potent and selective peptide deformylase inhibitors. J Med Chem (2001) 44(12):1847-1852.
70. Takayama W, Shirasaki Y, Sakai Y, Nakajima E, Fujita S, Sakamoto-Mizutani K, Inoue J: Synthesis and PDF inhibitory activities of novel benzothiazolylidenehydroxamic acid derivatives. Bioorg Med Chem Lett (2003) 13(19):3273-3276.
71. Molteni V, He X, Nabakka J, Yang K, Kreusch A, Gordon P, Bursulaya B, Warner I, Shin T, Biorac T, Ryder NS et al : Identification of novel potent bicyclic peptide deformylase inhibitors. Bioorg Med Chem Lett (2004) 14(6):1477-1481.
72. Steward WP, Thomas AL: Marimastat: The clinical development of a matrix metalloproteinase inhibitor. Expert Opin Investig Drugs (2000) 9(12):2913-2922.
73. Beeley NR: Can peptides be mimicked? Drug Disc Today (2000) 5(8):354-363.
74. Gross M, Clements J, Beckett RP, Thomas W, Taylor S, Lofland D, Ramanathan-Girish S, Garcia M, Difuntorum S, Hoch U, Chen H, Johnson KW: Oral anti-pneumococcal activity and pharmacokinetic profiling of a novel peptide deformylase inhibitor. J Antimicrob Chemother (2004) 53(3):487-493.
75. Chen D, Hackbarth C, Ni ZJ, Wang W, Wu C, Young D, White RJ, Trias J, Patel DV, Yuan Z: In vitro evaluation of VRC3375, a potent peptide deformylase inhibitor. ICAAC (2000) 40:Abs 2175.
76. Giglione C, Meinnel T: Peptide deformylase as an emerging target for antiparasitic agents. Emerg Ther Targets (2001) 5(1):41-57.
77. Giglione C, Meinnel T: Organellar peptide deformylases: Universality of the N-terminal methionine cleavage mechanism. Trends Plant Sci (2001) 6(12):566-572.
78. Giglione C, Serero A, Pierre M, Boisson B, Meinnel T: Identification of eukaryotic peptide deformylases reveals universality of N-terminal protein processing mechanisms. EMBO J (2000) 19(21):5916-5929.
79. Meinnel T: Peptide deformylase of eukaryotic protists: A target for new antiparasitic agents? Parasitol Today (2000) 16(4):165- 168.
80. Giglione C, Vallon O, Meinnel T: Control of protein life-span by N-terminal methionine excision. EMBO J (2003) 22(1):13-23.
81. Serero A, Giglione C, Meinnel T: Distinctive features of the two classes of eukaryotic peptide deformylases. J Mol Biol (2001) 314(4):695-708.
82. Nguyen KT, Hu X, Colton C, Chakrabarti R, Zhu MX, Pei D: Characterization of a human peptide deformylase: Implications for antibacterial drug design. Biochemistry (2003) 42(33):9952- 9958.
83. Serero A, Giglione C, Sardini A, Martinez-Sanz J, Meinnel T: An unusual peptide deformylase features in the human mitochondrial N-terminal methionine excision pathway. J Biol Chem (2003) 278(52):52953- 52963.
84. Waller AS, Clements JM: Novel approaches to antimicrobial therapy: Peptide deformylase. Curr Opin Drug Discovery Dev (2002) 5(5):785-792.
85. Margolis PS, Hackbarth CJ, Young DC, Wang W, Chen D, Yuan Z, White R, Trias J: Peptide deformylase in Staphylococcus aureus: Resistance to inhibition is mediated by mutations in the formyltransferase gene. Antimicrob Agents Chemother (2000) 44(7):1825-1831.
86. Apfel CM, Locher H, Evers S, Takacs B, Hubschwerlen C, Pirson W, Page MG, Keck W: Peptide deformylase as an antibacterial drug target: Target validation and resistance development. Antimicrob Agents Chemother (2001) 45(4):1058-1064.
87. Giglione C, Meinnel T: Resistance to anti-peptide deformylase drugs. Expert Opin Ther Targets (2001) 5(3):415-418.
88. Margolis P, Hackbarth C, Lopez S, Maniar M, Wang W, Yuan Z, White R, Trias J: Resistance of Streptococcus pneumoniae to deformylase inhibitors is due to mutations in def B. Antimicrob Agents Chemother (2001) 45(9):2432-2435.
89. Johnson ID, Waller A, Clements JM: Characterisation of in vitro-generated Streptococcus pneumoniae mutants with decreased sensitivity to peptide deformylase inhibitors. ICAAC (2002) 42:Abs F-1681.
90. Ogorzalek Loo RR, Dunham S, Kuhn S, Olson E, Holler T: Mass spectrometry, bacteria, and drug discovery: Targeting peptide deformylase. American Society for Mass Spectrometry Conference on Mass Spectrometry and Allied Topics, Chicago, USA (2001) 49.
91. Jones RN, Rhomberg PR: Comparative spectrum and activity of NVP-PDF386 (VRC4887), a new peptide deformylase inhibitor. J Antimicrob Chemother (2003) 51(1):157-161.
92. Jones RN, Fritsche TR, Sader HS: Antimicrobial spectrum and activity of NVP PDF-713, a novel peptide deformylase inhibitor, tested against 1,837 recent Gram-positive clinical isolates. Diagn Microbiol Infect Dis (2004) 49(1):63-65.
93. Azoulay-Dupuis E, Mohler J, Bedos JP: Efficacy of BB-83698, a novel peptide deformylase inhibitor, in a mouse model of pneumococcal pneumonia. Antimicrob Agents Chemother (2004) 48(1):80-85.
94. Genome Therapeutics Corp: Genome Therapeutics Corp - Form 10-K. Annual Report (2004):March 04.
95. Gross M, Clements J, Beckett RP, Thomas W, Taylor S, Lofland D, Ramanathan-Girish S, Garcia M, Difuntorum S, Hoch U, Chen H et al: Oral anti-pneumococcal activity and pharmacokinetic profiling of a novel peptide deformylase inhibitor. J Antimicrob Chemother (2004) 53(3):487-493.
96. Bowker KE, Noel AR, MacGowan AP: In vitro activities of nine peptide deformylase inhibitors and five comparator agents against respiratory and skin pathogens. Int J Antimicrob Agents (2003) 22(6):557-561.
97. Lopez S, Hackbarth C, Kubo A, Press B, Wu C, Gomez M, Asano R, Jain R, Sundaram R, Alvarez S, Patel D et al: In vitro microbiological profile of VRC4887 (NVP-PDF386), a potent peptide deformylase inhibitor. ICAAC (2002) 42:Abs F-1672.
98. Wise R, Andrews JM, Ashby J: In vitro activities of peptide deformylase inhibitors against Gram-positive pathogens. Antimicrob Agents Chemother (2002) 46(4):1117-1118.
99. Roblin PM, Hammerschlag MR: In vitro activity of a new antibiotic, NVP-PDF386 (VRC4887), against Chlamydia pneumoniae. Antimicrob Agents Chemother (2003) 47(4):1447-1448.
100. Cynamon MH, Alvirez-Freites E, Yeo AE: BB-3497, a peptide deformylase inhibitor, is active against Mycobacterium tuberculosis. J Antimicrob Chemother (2004) 53(2):403-405.
101. Azoulay-Dupuis E, Mohler J, Bédos J: PDF inhibitors have potent in vivo efficacy and a low propensity for resistance development in a mouse model of pneumococcal pneumonia. ICAAC (2002) 42:Abs B-707.
102. Noel A, Bowker KE, Howe RA, MacGowan AP: Emergence of resistance in S. pneumoniae to peptide deformylase inhibitors in comparison to fluoroquinolones. ICAAC (2002) 42:Abs F-1680.
103. Jones RN, Moet GJ, Sader HS, Fritsche TR: Potential utility of a peptide deformylase inhibitor (NVP PDF-713) against oxazolidinone-resistant or streptogramin-resistant Gram-positive organism isolates. J Antimicrob Chemother (2004) 53(5):804-807.
104. Lofland D, Difuntorum S, Waller A, Clements JM, Weaver MK, Karlowsky JA, Johnson K: In vitro antibacterial activity of the peptide deformylase inhibitor BB-83698. J Antimicrob Chemother (2004) 53(4):664-668.
105. Bozdogan B, Esel D, Whitener C, Browne FA, Appelbaum PC: Antibacterial susceptibility of a vancomycin-resistant Staphylococcus aureus strain isolated at the Hershey Medical Center. J Antimicrob Chemother (2003) 52(5):864-868.
106. Shlaes DM: The abandonment of antibacterials: Why and wherefore? Curr Opin Pharmacol (2003) 3(5):470-473.
107. Bracchi-Ricard V, Nguyen KT, Zhou Y, Rajagopalan PT, Chakrabarti D, Pei D: Characterization of an eukaryotic peptide deformylase from Plasmodium falciparum. Arch Biochem Biophys (2001) 396(2):162-170.
108. Wiesner J, Sanderbrand S, Altincicek B, Beck E, Jomaa H: Seeking new targets for antiparasitic agents. Trends Parasitol (2001) 17(1):7-8.
109. Mishra RC, Tripathi R, Katiyar D, Tewari N, Singh D, Tripathi RP: Synthesis of glycosylated β-amino hydroxamates as new class of antimalarials. Bioorg Med Chem (2003) 11(24):5363-5374.
110. Kumar A, Nguyen KT, Srivathsan S, Ornstein B, Turley S, Hirsh I, Pei D, Hol WG: Crystals of peptide deformylase from Plasmodium falciparum reveal critical characteristics of the active site for drug design. Structure (2002) 10(3):357-367.
111. NEWBIOTICS INC (Sergeeva M, Doppalapudi V): Peptide deformylase activated prodrugs. WO-02089739 (2002).
112. VERSICOR INC (Patel D, Ngu K, Zhou J): Methods for solid phase synthesis of mercapto compounds and derivatives and combinatorial libraries. US-06448058 (2002).
113. NOVARTIS AG (Patel D, Yuan Z, Jain R, Lewis J, Jacobs J): Novel bicyclic pyrrolidine compounds useful as PDF inhibitors for the treatment of bacterial infections. WO-02102791 (2002).
114. SMITHKLINE BEECHAM CORP (Aubart K, Christensen S, Briand J): Novel method of treating bacterial infections caused by staphylococci, streptococci and enterococci using N-formyl-N-hydroxy-(substituted aryl)alkylamine derivatives. WO-00185160 (2001).
115. VERSICOR INC (Patel D, Ngu K): Methods for solid-phase synthesis of hydroxylamine compounds and derivatives and combinatorial libraries thereof. WO-09957097 (1999).
116. SMITHKLINE BEECHAM CORP (Bhat A, Christensen S, Frazee J, Head M, Leber J, Li M): Novel N- hydroxyphenylacetamide derivatives useful as peptide deformylase inhibitors for the treatment of bacterial infection. WO-02081426 (2002).
117. AVENTIS PHARMA SA (Capet M, Genevois-Borella A, Martin J-P, Mikol V, Carrez C, Wentzler S): Hydroxamic acid macrocyclic derivates. WO-01040198 (2001).
118. QUESTCOR PHARMACEUTICALS INC (Chong L, Frechette R, Scott C, Tester R, Smith W, Chiba K, Sakamoto M, Gluchowski C): Peptide deformylase inhibitors. WO-00228829 (2002).
119. SMITHKLINE BEECHAM CORP (Aubart K, Xiang J, Christensen S, Liao X, Cummings M): Novel N-(4- alkyl-2-oxopyrrolidin-3-yl)methyl-N-hydroxyformamide derivatives useful as peptide deformylase inhibitors. WO-02070540 (2002).
120. BRITISH BIOTECH PHARMACEUTICALS LTD (Hunter M, Beckett R, Clements J, Whittaker M): The use of N-formyl hydroxylamine derivatives as antibacterial agents. WO-00035440 (2000).
121. BRITISH BIOTECH PHARMACEUTICALS LTD (Beckett R, Whittaker M, Spavold Z): Novel bacterial polypeptide deformylase enzyme inhibitors. WO-00058294 (2000).
122. BRITISH BIOTECH PHARMACEUTICALS LTD (Todd R, Brookings D, Smith H, Thompson A, Beckett R): Novel hydroxamic acid and N-formyl hydroxylamine derivatives useful as antimicrobial agents. WO-00061134 (2000).
123. BRITISH BIOTECH PHARMACEUTICALS LTD (Hunter M, Beckett R, Clements J, Whittaker M, Davies S, Pratt L, Spavold Z, Launchbury S): Novel N-formyl hydroxylamine derivatives, useful as antibacterials. WO-00110835 (2001).
124. BRITISH BIOTECH PHARMACEUTICALS LTD (Beckett P, Launchbury S, Pain G, Pratt L): Hydroxamic acid or N-formyl hydroxylamine derivatives as inhibitors of bacterial polypeptide deformylase for treating microbial infections. WO-00241886 (2002).
125. BRITISH BIOTECH PHARMACEUTICALS LTD (Pratt L, Keavey K, Pain G, Mounier L): Novel hydroxamic acid and N-formyl hydroxylamine derivatives, useful as antibacterials. WO-00110834 (2001).
126. DE NOVO PHARMACEUTICALS LTD (Gane P, Porter B, Willems H, Beckett RP, Keavey K): Novel hydroxamic acid and N-formyl hydroxylamine derivatives with bacterial polypeptide deformylase inhibitory activity. WO-03048115 (2003).